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BACKGROUND
Injection Drug Use
Common recreational drugs, such as heroin, methamphetamine, cocaine, and ketamine
are injected into the body using syringes/needles subcutaneously, intravenously, and
intramuscularly (National Institute on Drug Abuse, 2020). The practice of injection drug use
introduces a significantly higher risk of receiving and transmitting infectious diseases such as
HIV and hepatitis C due to practices such as sharing syringes, needles, and drug preparation
supplies (Centers for Disease Control, n.d.). Injection drug use is the second riskiest behavior
associated with new HIV infections, and 68% of hepatitis C diagnoses in 2016 can be attributed
to injection drug use (Centers for Disease Control, 2018) (Centers for Disease Control, n.d.).

Injection Drug Use Distribution in United States
A meta-analysis study estimated that in 2014, 2.6% of the U.S. population injected drugs
recreationally (Lansky et al., 2014). At the national level, trends in injection drug use in the
United States have been relatively stable for the past 20 years, but have steadily risen in some
subpopulations, including adolescents and African Americans (Harrison & Blonigen, 2017).
While trends of injection drug use are seemingly stable at the national level, there is much
variability at the regional level, often due to regional differences in the preference of certain
recreational drugs (Harrison & Blonigen, 2017). A report based on the National Drug Use and
Health Survey found that individuals injecting drugs in southern and western regions favored
stimulant drugs such as cocaine and methamphetamines, while their mid-western and
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northeastern counterparts were primarily injecting depressant substances, such as heroin
(Substance Abuse and Mental Health, 2007).
Injection Drug Use Distribution in Texas
Information on the prevalence and distribution of injection drug use in the state of Texas
is relatively limited, although some state surveillance systems such as the National Drug Early
Warning System (NDEWS) and Dallas, Texas’ National HIV surveillance System (NHBS) aim
to provide point estimates. A state-level summary analysis of the 2016 Treatment Episodes Data
Set (TEDS) admissions data reported that 33% of all patients admitted into public Texas
treatment facilities injected drugs (Maxwell, 2017). The NDEWS reported 85% of heroin users,
31% of methamphetamine users, and 2% of cocaine users in Texas treatment facilities were
primarily using injection as their preferred method of administration (National Drug Early
Warning System, 2018). In regards to the type of drugs being injected, the 2012 Dallas NHBS
reported that the most commonly injected drug in Texas is heroin, followed by speedball
(cocaine-heroin combination), and cocaine (Texas Department of State, 2012). Literature
regarding trends and characteristics of injection drug users in Texas is overall limited making it
difficult for Texas treatment programs and facilities to make decisions about their patient
population.

Public Health Significance
Injection drug use is now the most common mode of transmission for hepatitis C (Centers
for Disease Control, 2020a). Hepatitis C is an infection of the liver caused by the pathogenic
virus, hepatitis C (HCV), which is transmitted via blood to blood contact, most commonly
through shared needles. Acute hepatitis C is a short-term illness caused by HCV and is
6

characterized by jaundice, nausea/vomiting, abdominal pain, and joint pain. However, only 20%30% of individuals with acute hepatitis C will develop symptoms; leaving the majority of cases
unidentified and untreated. Approximately 75-85% of individuals with acute hepatitis C will
develop a chronic hepatitis C infection (Centers for Disease Control, 2020a). Chronic hepatitis C
that is left untreated can lead to severe health problems including cirrhosis of the liver, liver
failure, liver cancer, and death (Centers for Disease Control, 2020a). Approximately 10%-20%
of those infected with HCV will develop cirrhosis, and 3-6% of those with cirrhosis will go into
liver failure (Centers for Disease Control, 2020a).
There are an estimated 205,800 persons living with HCV in Texas, where the rate of
HCV is 1,040 cases per 100,000 persons (National Institute on Drug Abuse, 2019). Of those who
have HCV in Texas, 50-90% are co-infected with HIV and inject drugs (Texas Department of
State, 2018). In the wake of the U.S. opioid crisis, while the public and programs are focused
primarily on the prevalence of drug use and overdose, chronic illnesses, such as hepatitis C from
injection drug, are often overlooked. Because injection drug use is the largest risk factor for
HCV, it is important to assess the magnitude and trends of injection drug use in order to evaluate
resources for PWID and HCV. As of 2017, only 35% of all substance use treatment facilities
screen for HCV (Substance Abuse and Mental Health, 2017a). A recent survey of Texas
STD/HIV clinics, federally qualified health centers and treatment facilities found that 61% of
surveyed facilities reported not providing hepatitis testing because of capacity and lack of
funding (Texas Department of State, 2018). Evaluating proportions and trends of injection drug
use may provide insight into the types of services and resources that treatment facilities may
need to provide such as HCV testing.
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Challenges with Injection Drug Use Data
Some of the major challenges of tracking injection drug use is its illicit status, reporting
bias due to stigma, and the transient nature of the people who use drugs (Harrison & Blonigen,
2017). While these limitations exist, federal surveillance systems aim to provide valid estimates
of use. A meta-analysis of the National Survey of Drug Use and Health (NSDUH), National
Health and Nutrition provide Examination Survey (NHANES), and the National Survey of
Family Growth (NSFG) provided estimates of the proportion of people who inject drugs (Table
1) (Lansky et al., 2014). While nationally representative surveys aim to provide point estimates
at the national level, the estimates are highly variable by region and state and cannot be relied
upon to represent estimates of PWID in Texas. In this thesis, the Treatment Episodes Data SetAdmissions (TEDS-A) will be utilized to estimate the proportions of injection drug use. Unlike
other national surveys, the TEDS-A data can be analyzed at the state level, and is one of the few
data sources that provide data specific to people who use drugs; a population that is otherwise
difficult to reach. TEDS-A data cannot provide commentary on the trends of the drug using
population as a whole, it can provide some context for the population being treated in publicly
funded Texas treatment facilities, and can be leveraged to modify and fund programs
accordingly.
Aims and Objectives
The overall objective of this thesis is to establish a trend in the prevalence of injection
drug use among individuals admitted into publicly funded Texas treatment facilities. The
analysis was conducted using data from SAMSHA's TEDS-A system from 2013 to 2017. To
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provide further context, analyses were stratified by race, ethnicity, gender, age, and by the three
most commonly injected drugs in the U.S.: heroin, methamphetamine, and cocaine.

METHODS
Study Design
This is a serial cross-sectional secondary analysis of drug treatment admissions records
from the TEDS-A from years 2013-2017. The prevalence of injected drug use was calculated for
each year and analyzed across the five-year period using a chi-square test to determine the
presence of significant change in injection drug use from 2013 to 2017. Prevalence of injection
drug use also will be calculated for each year by drug type (heroin, methamphetamine, and
cocaine), age, sex, ethnicity and race, and will be analyzed for trends using a chi-square test.
Study Setting
TEDS-A data obtained from the state of Texas were examined. The number of Texas
treatment facilities receiving public funds varies by year (Table 2) (Substance Abuse and Mental
Health, n.d.a). Patients in TEDS-A records can be admitted into these treatment facilities through
self-referral, healthcare providers, employee assistance programs, schools, drug/alcohol care
providers, community referrals, or by court order (Center for Behavioral Health Statistics and
Quality, n.d.)
Study Subjects
Study subjects (n= 191,878) are individuals in Texas who have been admitted to a
publicly funded treatment facility for drug and/or alcohol abuse and are over the age of 12 years.
Records in TEDS-A datasets are not per individual, but are per admission episode. Admissions
entries in Texas in which the primary route of drug administration was injection were examined.
9

In 2017 this included n= 38,819 admission episodes, in 2016 n=36,528 admission episodes, in
2015 n= 37,370 admission episodes, in 2014 n= 39,485 admission episodes, and in 2013 n=
39,676 admission episodes.

Data Source
This thesis utilized the TEDS-A dataset, which is derived from the parent dataset, TEDS
(Treatment Episode Data Set). The TEDS series is a national database that collects state-reported
data and administrative records that are abstracted from publicly funded substance use treatment
facilities. The primary purpose of TEDS is to provide data on substance use facility services,
client demographics, and client substance use at the state and national level. TEDS-A Dataset is
one of two subsets of the parent dataset, Treatment Episodes Data Set (TEDS). The other sub-set
of TEDS, TEDS-D (Discharge), includes only discharge data from treatment facilities. TEDS
dataset is the only database that collects and publishes substance abuse treatment at the client
level, and is often leveraged for program and policy decision-making (Substance Abuse and
Mental Health, n.d.b). TEDS-A data comes from record abstracts and because TEDS-A is a
subset of TEDS, discharge and length of stay information can be linked for a complete
admission/discharge episode. Data are entered by treatment facilities staff members and
submitted to SAMHSA. The list of variables utilized in this thesis can be found in Table 3.

Data Analysis
The prevalence estimates and confidence intervals (95%) of injection drug use were
calculated for each year (n=5) for every category of interest. The prevalence estimates were then
used to compute a chi-square test to determine if there was a statistically significant difference
10

between one or more of the prevalence estimates in each category. The chi-square test was
chosen for significance testing because the primary route of administration use was calculated
into a binary field (inject/no inject) and was compared to the other categorical variable, year of
admission. Categories that yielded a significant p-value (p < 0.05) with the chi-square test were
then examined more closely to determine in which years the prevalence significantly increased
or decreased. Significant differences between two prevalence estimates were determined by
reviewing the confidence interval overlap. When the 95% confidence intervals between two
proportions did not overlap, significance (p < 0.05) was assumed. This assumption can be made
because an estimate with confidence intervals outside of the 95% confidence intervals of another
estimate are outside of the null (the estimate) at a significance level of p = 0.05. Confidence
intervals that overlapped cannot be assumed as not-significant due to a higher risk of type II
error, so prevalence estimates with overlapping confidence intervals were tested using a twosample test of proportions. Throughout the analysis, the chi-square test acted as an initial
screening for significant changes, followed by the year-to-year prevalence comparison which
provided a more detailed narrative of those changes.
RESULTS
All Injection Drug Use
The calculated prevalence estimates and confidence intervals (95%) can be seen in Table
4. The chi-square test for injection drug yielded a significant p-value (p = 0.000), suggesting that
one or more of the prevalence estimates significantly differed. The prevalence in injection drug
use significantly increased between 2013 (17.56%) and 2014 (18.16%) (p = 0.0251), and
between 2014 and 2015 (20.82%) with no confidence interval overlap (p < 0.05). The difference
in injection drug use between 2015 (20.82%) and 2016 (20.80%) was negligible with no
11

significant difference (p=0.9466). However, the prevalence of injection drug use then decreased
significantly from 2016 (20.80%) to 2017 (19.13%) with no confidence interval overlap (p <
0.05).
Injection Drug Use by Demographics
Injection drug use among males increased significantly between 2013 (17.71%), 2014,
(18.99%), and 2015 (21.72%) with no overlapping confidence intervals (p < 0.05). The
prevalence in injection drug use for males decreased between 2015 (p= 0.295) and 2016
(21.31%), and then significantly dropped in 2017 (19.62%) with no confidence interval overlap
(p <0.05). Injection drug use among females decreased between 2013 (17.34%) and 2014
(16.98%) (p =0.3904), but then significantly (p <0.05) increased from 2014 (16.98%), 2015
(19.46%), and 2016 (20.05%), followed by a significant decrease in 2017 (18.41%) with no
confidence interval overlaps. All categories of race experienced significant changes in injection
drug use between 2013 and 2017 with the exception of Asian and Multi-racial admissions.
Overall, White admissions had the highest prevalence of injection drug use compared to other
categories of race. The overall prevalence of injection drug use in Black admissions was lower
than any other racial category, and was the only category of race that shows a significant decline
in injection drug use between 2015 (6.15%) and 2016 (4.81%) with no confidence interval
overlap (p< 0.05) (Figure 1). The pattern of injection drug use in Native Americans was
dissimilar to other racial categories and the overall trend in injection drug use. Between 2015 and
2016, injection drug use in other race categories experienced a slight decrease, but in Native
Americans, injection drug use increased significantly by 8.27% (p <0.05) (Figure 1). Injection
drug use for both Hispanics and non-Hispanics changed significantly between 2013 and 2017
(p= 0.000). Injection drug use for Hispanics and non-Hispanics followed the same pattern of
12

trend with the exception of a significant decline in injection drug use in Hispanic admissions
between 2013 (17.97%) and 2014 (14.49%) (p < 0.05). The age groups with the highest overall
prevalence in injection drug use were those ages 20-29 and 30-39 (Figure 2). In contrast, the
age groups with the lowest prevalence in injection drug use were those ages 12 - 19.

Injection Drug Use by Drug Type
The chi-square test only yielded significant results for heroin (p = 0.000) and for
methamphetamines (p = 0.001). Injection drug use in those who were admitted primarily for
heroin use significantly increased from 2013 (76.92%) to 2014 (78.38 %) (p = 0.0528), and from
2014 to 2015(80.93%) with no confidence interval overlap (p < 0.05). The prevalence of
injection drug use in those admitted primarily for methamphetamines did not change
significantly until 2016 to 2017, when the prevalence declined from 32.10% to 30.14% (p =
0.0238) (Figure 3).
DISCUSSION
The trend in overall injection drug use was representative of the trend in injection drug
use in the observed sub-categories: prevalence increased between 2013 and 2015, followed by a
decline between 2015 and 2017. While not all year-to-year change was significant for each
category, almost all categories of interest followed this same pattern. One of the potential
explanations for the increase between 2013 and 2015 is the introduction of illicitly manufactured
fentanyl (IMF), a synthetic opioid that was introduced to the markets in 2013, and is commonly
cut with heroin (Centers for Disease Control, 2020b). The introduction of IMFs in 2013 may
have had the strongest influence on the trend of injection drug use as heroin admissions made up
about 67.48% of all primary injection drug use between 2013-2017. The cause of the decline in
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injection drug use between 2016 and 2017 is difficult to ascertain, but it may be the result of
harm reduction efforts outside of treatment facilities. At the individual level, harm reduction
refers to interventions and practices aimed to reduce the negative health and social consequences
of drug use without the cessation of drug use (Canadian Pediatric Society, 2008). Harm
reduction interventions specifically for people who inject drugs aim to mitigate physical injury
due to injections and the transmission of hepatitis C and HIV (Guidelines for the Screening,
2014). Harm reduction intervention methods that may cause a decrease in injection drug use
include the promotion of non-injection routes of administration, injection cessation, intermittent
injections, and educating users about the HCV and HIV risk (United Nations, 2007). Methods
such as these have been shown to be effective in reducing HIV and hepatitis C infections in
people who inject drugs, and may become more widely accepted and practiced as the research
continues to develop (Page et al., 2013).
Compared to national-representative prevalence estimates from SAMHSA’s TEDS-A
reports, the prevalence estimates of injection drug use in Texas were consistently higher than that
of the national estimates from 2013 and 2017 (Department of Health and Human Services, n.d.).
This was especially true for injection drug use among heroin admissions in which the prevalence
of injection drug use in Texas was 14.58% higher than the national estimate in 2017 (Substance
Abuse and Mental Health, 2019). Reasons for variability in injection drug use could be
dependent on region and the chemical properties of the drugs available in that region. Heroin is
the best example of this; heroin that is salt-based (i.e. black tar or columbian-sourced powder)
can easily be injected while other forms that are not salt-based are not easily injectable and are
more often smoked (Mars, Ondocsin, & Ciccarone, 2018). Heroin that is most available in Texas
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as of 2017 is Mexican black tar and powdered brown heroin, both of which are salt-based and
most easily administered through injection (Maxwell, 2017).
One of the more interesting injection drug use trends among the demographics examined
in this analysis was the significant increase in injection drug use among Native Americans
between 2015 and 2016. This 14.27% increase greatly differed from other categories of race that
either declined or changed insignificantly. By 2017, the race category with the highest
prevalence of injection drug use were those who were white (22.27%), followed by those who
were multi-racial (21.82%) and those who were Native American (19.39%). While the cause of
the increase of injection drug use in Native Americans is unclear, it may be an indicative of the
need for an at-risk public health intervention.
The present prevalence estimates and trends in injection drug use may provide supportive
evidence for program planning or determining funding allocations for treatment facilities. The
opportunity to evaluate funding and a facilities capacity to expand services, such as hepatitis C
testing, generally happens on a 2-year cycle based on the Substance Abuse Prevention and
Treatment Block Grant (Substance Abuse and Mental Health. 2017b). With approximately ⅕ of
all admissions to treatment facilities primarily injecting drugs, treatment facilities should
consider offering or expanding hepatitis C testing because of the risk associated with injection
drug use. While injection drug use decreased between 2016 and 2017, the prevalence in 2017 is
still 1.57% higher than it was in 2013. Yet, the proportion of treatment facilities offering
hepatitis C testing in Texas has not changed accordingly between 2013 (35.8%) and 2017
(35.5%) (Substance Abuse and Mental Health, n.d.a). Treatment facilities are one of the few
places that can systematically identify people who inject drugs because of TEDS-A reporting,
and therefore can identify those who may need hepatitis C testing upon admissions. The
15

accessibility of hepatitis C testing is also important because a large majority of admissions (85%
as of 2017) are uninsured and are unlikely getting tested and treated prior to their admission.
While the TEDS-A data presented in this thesis can be useful in describing the
characteristics of admitted patients, it is not representative of the drug using population outside
of treatment facilities. The results in the present study cannot be extended to the general public
or even to private funded treatment facilities because those populations are simply not
represented in this data-set. Despite its limitations, it is important that Texas and other states
regularly surveil TEDS-A data and leverage it accordingly to better serve their patients. The
focus of future research may be determining what has prompted the recent decline in injection
drug use, or determining if there are successful harm reduction interventions that could be more
widely implemented.
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APPENDIX
Table 1.
National Survey

Est. Proportion of PWID (%)
(CI 95%)

National Survey of Drug Use and Health

0.22
(0.19, 0.25)

National Health and Nutrition Provide Examination Survey

0.34
(0.24, 0.48)

National Survey of Family Growth

0.36
(0.27, 0.46)

Combined Estimate

0.30
(0.19, 0.41)

Table 2.
Publicly Funded Treatment Facilities in Texas by Year
Year

No.

% of total
facilities

2017

230

53.4%

2016

245

50.2%

2015

228

51.6%

2014

*

*

2013

253

54.9%

* Data not available
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Table 3.

TEDS-A Variables

Oral
Route of administration
(primary, secondary, tertiary)
Smoking
Inhalation
Injection
Other
Sex

Male
Female

Race

Alaska Native (Aleut, Eskimo, Indian)
American Indian (Other than Alaska Native)
Asian or Pacific Islander
Black or African American
White
Other single race
Two or more face
Native Hawaiian or Other Pacific Islander
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Ethnicity

Puerto Rican
Mexican
Cuban or other specific Hispanic
Not of Hispanic of Latino origin
Hispanic of Latino, specific origin not specified
None
Alcohol
Cocaine/Crack
Marijuana/Hashish

Substance Use
(primary, secondary, tertiary)

Heroin
Non-Prescription Methadone
Other Opiates and Synthetics
PCP
Other Hallucinogens
Methamphetamines
Other Amphetamines
Other Stimulants
Benzodiazepines
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Barbiturates
Other non-Barbiturate sedatives or hypnotics
Inhalants
Over-the-counter Medications
Other
12-14 years
15-17 years
18-20 years
21-24 years
Age
25-29 years
30-34 years
35-39 years
40-44 years
45-49 years
50-54 years
55-64 years
65 + years

24

Table 4.
Prevalence of Injection Drug Use by Year
CI 95%, Chi-Square p-values
2013

2014

2015

2016

2017

P-value

.1756
(.1719, .1794)

.1816
(.1779, .1855)

.2082
(.2041, .2123)

.2080
(.2039, .2122)

.1913
(.1874, .1952)

0.000

Male

.1771
(.1722, .1820)

.1899
(.1849, .1950)

.2172
(.2118, .2227)

.2131
(.2077, .2186)

.1962
(.1911, .2014)

0.000

Female

.1734
(.1676, .1793)

.1698
(.1640, .1757)

.1946
(.1883, .2010)

.2005
(.1941, .2070)

.1841
(.1782, .1903)

0.000

White

.2001
(.1957, .2046)

.2091
(.2047, .2136)

.2362
(.2315, .2410)

.2371
(.2323, .2419)

.2227
(.2181, . 2273)

0.000

Black

.0464
(.0415, .0517)

.0422
(.0374, .04756)

.0615
(.0554, .0680)

.0481
(.0426, .0541)

.0395
(.0349, .0445)

0.000

Native American

.1702
(.1315, .2148)

.1265
(.0927, .1671)

.1184
(.0795, .1676)

.2606
(.2028, .3254)

.1939
(.1479, .2470)

0.000

Asian

*

.0778
(.0421, .1294)

.104
(.0565, .1713)

.0986
(.0550, .1599)

.1186
(.0756, .1735)

0.778

Multi-racial

*

.2680
(.1997, .3455)

.2394
(.1719, .3182)

.1759
(.1276, .2333)

.2182,
(.1779, .2628)

0.186

Hispanic

.1797
(.1751, .1844)

.1449
(.1387, .1513)

.1710
(.1641, .1781)

.1673
(.1603, .1745)

.1545
(.1477, .1614)

0.000

Non-Hispanic

.1663
(.1600, .1727)

.1985
(.1938, .2034)

.2241
(.2191, .2292)

.2251
(.2200, .2303)

.2060
(.2013, .2108)

0.000

Injection Drug Use

Gender

Race

Ethnicity

Age

25

12-19

.1279
(.1215, .1345)

.0459
(.0407, .0516)

.0632
(.0563, .0704)

.0551
(.0485, .0622)

.0439
(.0383, .0499)

0.012

20 - 29

.2274
(.2204, .2344)

.2293
(.2217, .2370)

.2598
(.2517, .2680)

.2544
(.2462, .2627)

.2194
(.2117, .2272)

0.000

30 - 39

.1774
(.1690, .1861)

.2270
(.2193, .2349)

.2526
(.2446, .2609)

.2514
(.2435, .2594)

.2387
(.2312, .2463)

0.000

40 - 49

.1369
(.1277, .1457)

.1580
(.1490, .1673)

.1712
(.1617, .1810)

.1953
(.1851, .2058)

.1926
(.2828, .2027)

0.000

> 50

.1598
(.1439, .1768)

.1463
(.1361, .1569)

.1638
(.1529, .1751)

.1466
(.1360, .1568)

.1498
(.1391, .1609)

0.099

Heroin

.7692
(.7684, . 7797)

.7838
(.7733, .7941)

.8093
(.7996, .8187)

.8143
(.8045, .8239)

.7948
(.7846, .8047)

0.000

Methamphetamine

.3382
(.3238, .3524)

.3280
(.3147, .3415)

.3302
(.3171, .3434)

.3210
(.3089, .3333)

.3014
(.2895, .3135)

0.001

Cocaine

.0270
(.0223,. .0323)

.0274
(.0224, .0331)

.0255
(.0204, .0316)

.0211
(.0163, .0270)

.0196
(.0148, .0234)

0.145

Drug Type

Figure 1.
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